Analysis Group Consultants to Present at ISPOR 2026
Event: ISPOR 2026 Dates: 17–20 May 2026 Host: ISPOR – The Professional Society for Health Economics and Outcomes Research Location: Philadelphia, PA
Analysis Group, a global leader in health economics and outcomes research (HEOR), epidemiology, and market access, will present an educational symposium, join two panel discussions, contribute to a podium presentation, and share 25 research posters at ISPOR 2026, which will be held at the Pennsylvania Convention Center in Philadelphia, PA.
Managing Principal Eric Wu, Principal Jimmy Royer, and Professor Liming Liang (Harvard T.H. Chan School of Public Health) will present an educational symposium titled “Driving the Next Era of Evidence-Based Medicine through AI, Diverse Data, and Collaboration.” The symposium will explore how cutting-edge GenAI methodology can be applied to develop comprehensive and up-to-date insights on diseases and treatment outcomes from heterogeneous data sources. Presenters will showcase the application of GenAI with digital twin methodologies to simulate the long-term progression of obesity and chronic cardiometabolic diseases.
The symposium will also introduce a new real-world evidence research initiative jointly launched by the Harvard T.H. Chan School of Public Health and Analysis Group, focused on advancing precision health through the application of AI to better understand disease pathways, treatment effectiveness, and personalized health. The symposium will be held on Tuesday, May 19, at 12:15 p.m.
Additional presentations:
- Managing Principal Min Yang will participate as a panelist in the forum titled “HEOR Skills Building: Essential Skills for the Future” on Monday, May 18, at 12:15 p.m.
- Principal Jimmy Royer will participate as a panelist in the forum titled “The Enduring Challenge of Medical Device Identification in Real-World Data: Is Artificial Intelligence Abstraction Ready for Broad Use and Acceptance?” on Monday, May 18, at 12:15 p.m.
- A study coauthored by Vice President Weiguang Xue, Manager Yanwen Xie, and Senior Analyst Jack Eales titled “Consideration of Indirect Effects in National Vaccine Evaluations and Recommendations: A Scoping Review” will be shared as a podium presentation on Monday, May 18, at 1:45 p.m.
Further details on these presentations and Analysis Group’s posters are available in our ISPOR 2026 Presentation Guide.
Associated People
Jimmy Royer
PrincipalDr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.
Weiguang Xue
Vice PresidentMr. Xue consults on cases involving health economics and outcomes research (HEOR). He specializes in using health economics analyses to inform product launch strategies, as well as decision making in early-stage clinical development. Mr. Xue has extensive experience in the economic evaluation of health technologies across multiple therapeutic areas, including oncology, infectious diseases, autoimmune diseases, central nervous system diseases, ophthalmology, and gynecology. His work includes cost-effectiveness analysis, budget impact analysis, systematic literature review, indirect treatment comparison, evaluation of health care resource use, global value dossier, and market access strategy. He has led successful health technology assessment (HTA) submissions to the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG). He has also developed global economic models across multiple indications and led country rollouts supporting market access in Europe, North America, and Asia.